Most inexpensive way is start with the use same 21-mer full-PS 2’-OMe splice-switching ASO, but add a single terminal fluorophore, preferably at the 5’ end or 3’ end, with a short flexible linker such as C6 or C12. (we normally use C6 unless probe is long)
Avoid internal labeling unless the sequence has already been validated with that modification, because internal dyes can disrupt RNA binding, splice-switching activity, and steric-blocking geometry.
Fluorophore choice
For confocal only, use Cy5, Alexa Fluor 647, or ATTO 647N. For in vivo / ex vivo IVIS, use a near-infrared dye, such as Cy5.5, IRDye 680RD, Alexa Fluor 680, or IRDye 800CW. But for preserving native ASO behavior, I would be cautious with large, highly charged, or very hydrophobic dyes. They may strongly alter biodistribution. A far-red dye like Cy5/Alexa 647 is often a reasonable compromise for tissue sections and confocal; 800CW-type dyes are better for IVIS but may perturb PK more.
Labeling position
Start with 5’-fluorophore-C6-ASO and compare to unlabeled ASO. Also consider synthesizing 3’-fluorophore-C6-ASO as a second pilot if budget allows. For splice-switching ASOs, the better end can be sequence- and target-dependent.
Critical controls
One should order at least:
- Unlabeled active ASO
- Fluorescent active ASO
- Fluorescent scrambled/non-targeting ASO with same chemistry and length
- Ideally, unlabeled scrambled ASO
Then test:
- Splice-switching activity in vitro versus the original ASO
- Dose-response shift after labeling
- Cell uptake/localization by confocal
- Ex vivo organ fluorescence after IV dosing
- Optional: LC-MS or hybridization assay for true ASO tissue concentration, because fluorescence alone may not equal intact ASO
Most important warning
For PK/biodistribution, fluorescence should be treated as a tracking tool, not definitive proof that the labeled ASO behaves identically to the parent ASO. The dye may remain after ASO degradation or may change tissue retention. Literature also notes that exogenous fluorescent tags can influence intracellular transport kinetics and may not fully represent the clinical/unlabeled oligo behavior.
We recommend a small pilot comparing 5’- and/or 3’-terminally labeled versions of the same full-PS 2’-OMe ASO using a far-red or near-infrared fluorophore. A terminal C6/C12 linker is preferred to minimize interference with target RNA binding. For confocal microscopy, Cy5/Alexa 647/ATTO 647N would be suitable. For IVIS or ex vivo whole-organ imaging, Cy5.5/IRDye 680/IRDye 800CW-type dyes may be considered, although larger NIR dyes may alter ASO protein binding, uptake, and biodistribution. We strongly recommend validating splice-switching activity and uptake against the unlabeled parent ASO before interpreting biodistribution data.